JPI InvestFrançais
JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool's data · not financial advice · full analysis (free)
All stocks › Health Care › RGEN

Are analysts right about Repligen (RGEN)?

Health Care · price $189 · median target $185 (-2%)
In short — Over the past 12 months, 35% of analyst price targets on Repligen turned out profitable, for an average return of +16% (across 82 timestamped calls). The current consensus is "Buy" with a median price target of $185 (-2% vs the current $189, from 9 analysts).

📈 See the interactive version (live chart) →

🔗 Related pages on Repligen — Financials & fundamentals  ·  If I had invested
Current price
$189
Median target (12 mo)
$185 -2%
Analyst accuracy (1 yr)
35%
Avg return / call (1 yr)
+16%
💰 Performance & « if I invested » 📊 Interactive analysis

Historical analyst accuracy

For Repligen, we replayed every analyst price target of the past 12 months and measured the real outcome: 35% were profitable, average return +16% (82 calls). At 3 months: +5% average return (50% profitable). The higher the %, the more often analysts were right on this stock.

Most reliable analysts on this stock (past track record)

Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.

Analyst / brokerCalls i% profitable iAvg return i
HC Wainwright & Co.1250%+27%
RBC Capital1010%-10%
JP Morgan825%+0%
Stifel757%+55%
SVB Leerink714%-1%

Frequently asked questions

Is Repligen a buy right now?

The analyst consensus on Repligen (RGEN) is "Buy" (21 bullish, 0 bearish calls over 12 months). This is not advice: historically, 35% of their targets on this stock turned out profitable over 1 year.

What is Repligen's price target?

The median 12-month price target is $185 (-2% vs $189), ranging from $150 to $225 (9 analysts).

Are analysts accurate on Repligen?

Over 1 year, 35% of analyst targets on Repligen were profitable, for an average return of +16% (across 82 timestamped calls). This is JPI Invest's accuracy metric.

What is the Repligen stock forecast?

Analysts target a median of $185 within 12 months, i.e. -2% vs the current price. The most bullish targets $225, the most cautious $150.

What is the Repligen stock forecast for 2026 or long term (2030)?

Note: analyst targets are 12-month (median $185, -2%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (35%), and the stock's past trajectory.

Is Repligen overvalued?

Detailed valuation data for Repligen is available in the interactive analysis.

📊 See the full interactive analysis of Repligen →

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free → How it works: the method →

⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.